ReviewJournal of internal medicine2013
Genetically engineered T cells for the treatment of cancer.
Review in Journal of internal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Protein catenation potentiates antitumor activity of malaria VAR2CSA navigation CAR-T cells in a mouse model of hematological malignancies.Journal for immunotherapy of cancer · 2025Article
- Cell-based therapies for the treatment of rheumatoid arthritis.Immunity, inflammation and disease · 2023Review
- Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors.Molecular therapy oncolytics · 2022Review
- Generating CAR T cells from tumor-infiltrating lymphocytes.Therapeutic advances in vaccines and immunotherapy · 2021Article
- Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.Frontiers in genetics · 2021Article
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview.Cancers · 2020Review
- CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.Frontiers in immunology · 2020Review
- Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering.Frontiers in immunology · 2020Article
- The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy.Cancers · 2019Review
- Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer.Oncology letters · 2018Article
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Laboratory investigation; a journal of technical methods and pathology · 2017Review
- In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy.BMC bioinformatics · 2016Article
- Immunology of hepatocellular carcinoma.World journal of hepatology · 2015Review
- Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2015Review
- Article
- CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes.Cancer gene therapy · 2014Article
- Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.BMC cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell immunotherapy is a promising approach to treat disseminated cancer. However, it has been limited by the ability to isolate and expand T cells restricted to tumour-associated antigens. Using ex vivo gene transfer, T cells from patients can be genetically engineered to express a novel T cell receptor or chimeric antigen receptor to specifically recognize a tumour-associated antigen and thereby selectively kill tumour cells. Indeed, genetically engineered T cells have recently been successfully used for cancer treatment in a small number of patients. Here we review the recent progress in the field, and summarize the challenges that lie ahead and the strategies being used to overcome them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.